Skip to main content

Advertisement

SpringerLink
Log in

Native aortic valve regurgitation: TAVR’s place in the PANTHEON

  • Critical Appraisal of Trials
  • Published:
Indian Journal of Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

The PANTHEON (Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a native valve) study examined transcatheter aortic valve replacement in patients with severe pure native aortic valve regurgitation. With a real-world dataset from 16 centres in Europe and the USA, the study encompassed 201 patients. The major complications included valve embolization or migration in 12.4%, moderate to severe aortic regurgitation in 9.5% cases and need for permanent pacemaker in 22.3% cases. Self-expanding and balloon-expandable devices demonstrated similar outcomes. Those experiencing valve embolization or migration had higher 1-year adverse event rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Data sharing is not applicable. We did not analyse or generate any datasets.

References

  1. Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON International Project. JACC Cardiovasc Interv. 2023;16:1974–85.

    Article  PubMed  Google Scholar 

  2. VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825–57.

  3. Vora AN, Sreenivasan J, Forrest JK. Progressing forward in transcatheter aortic valve replacement for pure aortic regurgitation. JACC Cardiovasc Interv. 2023;16:1986–9.

    Article  PubMed  Google Scholar 

  4. Jerez-Valero M, Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7:1022–32.

    Article  PubMed  Google Scholar 

  5. Daneault B, Koss E, Hahn RT, Kodali S, Williams MR, Généreux P, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2013;6:85–91.

    Article  PubMed  Google Scholar 

  6. Lasa G, Gaviria K, Sanmartín JC, Telleria M, Larman M. Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83:E112-118.

    Google Scholar 

  7. Wang Y, Yu S, Qian D, Li J, Fang Z, Cheng W, et al. Anatomic predictor of severe prosthesis malposition following transcatheter aortic valve replacement with self- expandable Venus-a valve among pure aortic regurgitation: a multicenter retrospective study. Front Cardiovasc Med. 2022;9:1002071.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Adam M, Tamm A, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. Transcatheter aortic valve replacement for isolated aortic regurgitation using a new self-expanding TAVR system. JACC Cardiovasc Interv. 2023;16:1965–73.

    Article  PubMed  Google Scholar 

  9. JenaValve Technology, Inc. A study to assess safety and effectiveness of the JenaValve TrilogyTM heart valve system in the treatment of high surgical risk patients with symptomatic, severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Sep [cited 2023 Sep 1]. Report No.: NCT04415047. Available from: https://clinicaltrials.gov/study/NCT04415047.

  10. JenaValve Technology, Inc. THE ALIGN-AR TRIAL: safety and effectiveness/performance of the transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 Sep 1]. Report No.: NCT02732704. Available from: https://clinicaltrials.gov/study/NCT02732704.

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, 124, EM Bypass, Mukundapur, Kolkata, 700099, India

    Pradeep Narayan

Authors
  1. Pradeep Narayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pradeep Narayan.

Ethics declarations

Ethical approval

Not applicable as a review article.

Informed consent

Not applicable as a review article.

Conflict of interest

The author declares no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narayan, P. Native aortic valve regurgitation: TAVR’s place in the PANTHEON. Indian J Thorac Cardiovasc Surg 39, 643–645 (2023). https://doi.org/10.1007/s12055-023-01609-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12055-023-01609-1

Keywords

Search

Navigation